EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Brentuximab vedotin in treating Chinese patients with lymphoma: A multicenter, real‐world study

Xudong Zhang, Honghan Qiao iD, Xiaofei Chai, Xue Gao, Rongjun Ma, Yufu Li, Zunmin Zhu, Mingzhi Zhang iD

Cancer Medicine · 2023

DOI: 10.1002/cam4.6733 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Cancer Medicine, 2023. Verfasst von Xudong Zhang und 7 weiteren Autor:innen. Beteiligte Einrichtung: The First Affiliated Hospital of Zhengzhou University, ZhengZhou, China. Hauptthemen laut MEDLINE: Hodgkin Disease, Immunoconjugates, Lymphoma. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Brentuximab vedotin (BV) was approved as a therapy for patients with CD30‐positive lymphoma in China in 2020 based on the results of multiple clinical trails. Few Chinese real‐world data of its use are yet available. Herein, we present the application situation of BV in patients with lymphoma among different hospitals in Henan province in China under real‐world conditions.

Methods

This was a multicenter and retrospective study in 104 patients with lymphoma who received BV for the first time between August 2020 and September 2022 across eight centers in Henan province. Data on the clinical use, effectiveness and adverse events (AEs) of BV were extracted from patient medical records. Short‐term effectiveness was assessed based on objective response rate (ORR), complete response (CR), partial response (PR), stable disease (SD) and progressive disease (PD). Progression‐free survival (PFS) and overall survival (OS) were calculated using Kaplan–Meier method. Safety was also evaluated in our study.

Results

104 lymphoma patients were enrolled in our study, who had completed a median of two cycles (range,1–8) of BV‐based treatment. A total of 72.1% of patients were relapsed/refractory (R/R) lymphoma, and only 27.9% were previously untreated lymphoma who received BV in frontline treatment settings. Among them who received effectiveness evaluation, the ORR achieved 64.5% (CR 25.8%, PR 38.7%). After a median follow‐up of 11 months, the 6‐month PFS rate and OS rate achieved 77.2% and 90.1% respectively, and the 12‐month PFS rate and OS rate achieved 77.2% and 79.9% respectively. In general, BV‐based treatment was well‐tolerated, with 38.5% incidence of grade ≥3 AEs. The most commonly reported AEs were hematologic disorders, especially neutropenia, with the incidence reaching 50.0%.

Conclusions

BV‐based regimens could be a promising therapeutic option with remarkable effectiveness and moderate toxicity in treating Chinese lymphoma patients with CD30 expression.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hodgkin DiseaseImmunoconjugatesLymphomaHumansBrentuximab VedotinRetrospective StudiesTreatment Outcome

Stichwörter der Autor:innen

brentuximab vedotineffectivenesslymphomareal-world studysafety

Substanzen

Brentuximab VedotinImmunoconjugates

Autor:innen und Institutionen

  • The First Affiliated Hospital of Zhengzhou University, ZhengZhou, China.
  • Henan Cancer Hospital, ZhengZhou, China.
  • Henan Provincial People's Hospital, ZhengZhou, China.

ORCID-Profile: Honghan Qiao, Mingzhi Zhang

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Zhang, X., Qiao, H., Chai, X., Gao, X., Ma, R., Li, Y., Zhu, Z., & Zhang, M. (2023). Brentuximab vedotin in treating Chinese patients with lymphoma: A multicenter, real‐world study. Cancer Medicine. https://doi.org/10.1002/cam4.6733

Vancouver

Zhang X, Qiao H, Chai X, Gao X, Ma R, Li Y, et al. Brentuximab vedotin in treating Chinese patients with lymphoma: A multicenter, real‐world study. Cancer Medicine. 2023. doi:10.1002/cam4.6733

BibTeX
@article{Zhang2023,
  author = {Zhang, Xudong and Qiao, Honghan and Chai, Xiaofei and Gao, Xue and Ma, Rongjun and Li, Yufu and Zhu, Zunmin and Zhang, Mingzhi},
  title = {Brentuximab vedotin in treating Chinese patients with lymphoma: A multicenter, real‐world study},
  journal = {Cancer Medicine},
  year = {2023},
  doi = {10.1002/cam4.6733}
}
Kostenlos starten →